Results of a randomized, placebo-controlled pharmaco-clinical study with a combined herbal preparation for the treatment of patients with somatoform disorders;Ergebnisse einer randomisierten, placebokontrollierten pharmakoklinischen Studie mit einem pflanzlichen Kombinationsprparat zur Behandlung von Patienten mit somatoformen Strungen

Schweizerische Zeitschrift fur GanzheitsMedizin

Volumn 24, Issue 5, 2012, Pages 284-286

  Melzer, Jörg ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HERBACEOUS AGENT; PLACEBO;

ARTICLE; CONTROLLED STUDY; HUMAN; RANDOMIZED CONTROLLED TRIAL; SOMATOFORM DISORDER;

EID: 84867253523     PISSN: 10150684     EISSN: 16637607     Source Type: Journal    
DOI: 10.1159/000342466     Document Type: Article

References (28)

1. Melzer J, Brignoli R, Saller R: Komplementärmedizin, Phytotherapie und Sojaisoflavone als Phytoöstrogene. Zentralbl Gynakol 2004;126:138-147.
2. García-García P, López-Muñoz F, Rubio G, Martín-Agueda B, Alamo C: Phytotherapy and psychiatry: bibliometric study of the scientific literature from the last 20 years. Phytomedicine 2008;15:566-576.
3. Melzer J, Saller R: Gibt es ein bestimmtes Menschenbild in der Naturheilkunde/Komplementärmedizin? Forsch Komplementmed 2006;13:210-219.
4. Sackett D, Strauss S, Richardson W, Rosenberg W, Haynes R: Evidence-Based Medicine. How to Practice and Teach EBM, ed 2. Edinburgh, Churchill Livingstone, 2000.
5. Kenny E, Muskin PR, Brown R, Gerbarg PL: What the general psychiatrist should know about herbal medicine. Curr Psychiatry Rep 2001;3:226-234.
6. Werneke U, Turner T, Priebe S: Complementary medicines in psychiatry: review of effectiveness and safety. Br J Psychiatry 2006;188:109-121.
7. Millan MC: Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006;110:135-370.
8. Wong EH, Nikam SS, Shahid M: Multiand single-target agents for major psychiatric diseases: therapeutic opportunities and challenges. Curr Opin Investig Drugs 2008;9:28-36.
9. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D: St John's wort for depression-an overview and meta-analysis of randomised clinical trials. BMJ 1996;313:253-258.
10. Linde K, Mulrow CD, Berner M, Egger M: St Johns wort for depression. Cochrane Database Syst Rev 2005;2:CD000448.
11. Linde K, Berner MM, Kriston L: St Johns wort for major depression. Cochrane Database Syst Rev 2008;4:CD000448.
12. Harter M, Klesse C, Bermejo I, et al.: Evidenzbasierte Therapie der Depression. Die S3-Leitlinie unipolare Depression. Nervenarzt 2010;81:1049-1068.
13. Holsboer-Trachsler E, Hättenschwiler J, Beck J, Brand S, Hemmeter UM, Keck ME, Rennhard S, Hatzinger M, Merlo M, Bondolfi G, Preisig M, Seifritz E, Attinger Andreoli Y, Gehret A, Bielinski D: Die somatische Behandlung der unipolaren depressiven Störungen. Schweiz Med Forum 2010;10:802-809.
14. Melzer J, Keck ME: Phytotherapie in der Psychiatrie-gestern, heute, morgen. Ars medici Thema Phytotherapie 2011;1:16-20.
15. Melzer J, Schrader E, Brattström A, Schellenberg R, Saller R: Fixed herbal drug Combination with and without butterbur (Ze 185) for the treatment of patients with somatoform disorders: randomized, placebo-controlled pharmacoclinical trial. Phytother Res 2009;23:1303-1308.
16. Carlini EA: Plants and the central nervous system. Pharmacol Biochem Behav 2003; 75:501-512.
17. European Scientific Cooperative On Phytotherapy (ESCOP) (ed): Melissae folium (Melissa Leaf). Stuttgart, Thieme, 2003, pp 324-328.
18. ESCOP: Passiflorae herba (Passion Flower). Stuttgart, Thieme, 2003, pp 359-364.
19. ESCOP: Valerianae radix (Valerian Root). Stuttgart, Thieme, 2003, pp 539-546.
20. Dhawan K, Dhawan S, Sharma A: Passiflora: a review update. J Ethnopharmacol 2004;94:1-23.
21. Kennedy DO, Little W, Scholey AB: Attenuation of laboratory-induced stress in humans after acute administration of Melissa officinalis (lemon balm). Psychosom Med 2004;66:607-613.
22. Arzneimittel-Kompendium der Schweiz®. Relaxane. Basel, Documed AG 2011. www.kompendium.ch/MonographieTxt. aspx?lang=de&MonType=fi.
23. Bickel D, Roder T, Bestmann HJ, Brune K: Identification and characterization of inhibitors of peptido-leukotriene-synthesis from Petasites hybridus. Planta Med 1994;60:318-322.
24. Kälin P: Gemeine Pestwurz (Petasites hybridus)-Portrait einer Arzneipflanze. Forsch Komplementärmed Klass Naturheilkd 2003; 10(suppl 1):41-44.
25. Giles M, Ulbricht, Khalsa KP, Kirkwood CD, Park, Basch E: Butterbur: an evidence-based systematic review by the natural standard research collaboration. J Herb Pharmacother 2005;5:119-143.
26. Dilling H, Mombour W, Schmidt MH (Hrsg): Weltgesundheitsorganisation. Internationale Klassifikation psychischer Störungen. ICD-10 Kapitel V (F). Klinischdiagnostische Leitlinien, ed 5. Bern, Hans Huber, 2005.
27. Unützer J, Klap R, Sturm R, Young AS, Marmon T, Shatkin J, Wells KB: Mental disorders and the use of alternative medicine: results from a national survey. Am J Psychiatry 2000;157:1851-1857.
28. Wahlström M, Sihvo S, Haukkala A, Kiviruusu O, Pirkola S, Isometsa E: Use of mental health services and complementary and alternative medicine in persons with common mental disorders. Acta Psychiatr Scand 2008;118:73-80.